Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization
Latest Information Update: 03 Sep 2024
At a glance
- Drugs Emiplacel (Primary)
- Indications Chronic limb-threatening ischemia; Peripheral arterial disorders
- Focus Registrational; Therapeutic Use
- Acronyms PACE
- Sponsors Pluri
- 29 Aug 2024 Status changed from active, no longer recruiting to completed.
- 31 Jan 2024 Results evaluating whether PLX-PAD would increase amputation-free survival in people with CLTI who were not candidates for revascularization, published in the British Journal of Surgery
- 13 Mar 2023 ccording to a Pluristem Therapeutics media release, Pluristem Therapeutics has changed its name to Pluri Inc.